Cidara Therapeutics Stock Investor Sentiment
| CDTX Stock | USD 23.81 0.19 0.79% |
Slightly above 59% of Cidara Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Cidara Therapeutics suggests that many traders are alarmed. Cidara Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cidara Therapeutics' earnings reports, geopolitical events, and overall market trends.
Cidara |
Cidara Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cidara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Cidara Therapeutics that are available to investors today. That information is available publicly through Cidara media outlets and privately through word of mouth or via Cidara internal channels. However, regardless of the origin, that massive amount of Cidara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cidara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cidara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cidara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cidara Therapeutics alpha.
Cidara Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Ra Capital Management, L.p. of 389716 shares of Cidara Therapeutics at 14.912 subject to Rule 16b-3 | 11/26/2024 |
2 | Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza | 12/04/2024 |
3 | Short Interest in Cidara Therapeutics, Inc. Expands By 6.0 | 12/16/2024 |
4 | Acquisition by Canale-theakston Carin of 16000 shares of Cidara Therapeutics at 22.81 subject to Rule 16b-3 | 12/17/2024 |
5 | Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders | 12/23/2024 |
6 | Acquisition by Les Tari of 150224 shares of Cidara Therapeutics at 10.75 subject to Rule 16b-3 | 01/03/2025 |
7 | Heres Why Cidara Therapeutics, Inc. Is Skyrocketing | 01/13/2025 |
8 | Cidara Therapeutics, Inc. Sees Large Increase in Short Interest | 01/17/2025 |
9 | Cantor Fitzgerald raises Cidara stock to Overweight - Investing.com | 01/27/2025 |
10 | Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference | 01/30/2025 |
11 | Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention - Seeking Alpha | 02/11/2025 |
12 | Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer | 02/18/2025 |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.